Observ Medical

[Quadruple]

Dette er gammelt nytt. Emisjonen ble ingen suksess, og selskapet trenger snart penger igjen.
Og dette vet du, Powertrade.

La oss slippe “Hegnar-tilstander” her.

[Powertrade]

Det er sant - gammel nytt - Så får vi håpe det genereres inntekter mer enn estimat.

Du håper på det du og Quadruple? For du eier aksjer i OBSERVE?

[Quadruple]

Har bare et lite antall. Som jeg hverken blir rik eller fattig av, uansett hvilken vei det går.

[Powertrade]

Et lite antall er jo relativt- Det kan være 50.000, 500.000 eller 5.000.000.

Jeg har et relativt stort antall - men det er jo og relativt.

Jeg blir relativt rik om det går rett vei !

Hva er forresten rikdom ?

[TekBot]

Observe Medical Annual Report for 2023

Oslo, 30 April 2024 - Observe Medical ASA (“the Company” or “Observe Medical”)
today announces that the Company has published its Annual Report for 2023. The
Annual Report was approved by the Board of Directors on 26 April 2024.
…

Vis børsmeldingen

“Despite some challenges, 2023 was a year of great achievements and exciting
opportunities. I am grateful for the dedication of the Observe Medical team and
the continued support of our shareholders. Our ambition and goals for the future
remain unchanged, and I look forward to updating you on our progress soon”
commented Jørgen Mann, Interim CEO of Observe Medical.

The Annual Report for 2023 is attached to this notice and available on the
Company’s website under the Investor Relations section. The auditor’s report,
which is incorporated in the annual report, includes a statutory emphasis of
matter relating to the further financing of the Company.

For further information, please contact:

Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, Interim CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care,
in combination with targeted M&A.

The Company is headquartered in Oslo, Norway, with additional offices in Narvik,
Norway and Gothenburg, Sweden, and subsidiaries in Finland and the US. In
addition, Observe Medical has a direct sale organization in the Nordics and a
distributor network internationally.

Further information is available at www.observemedical.com.

Kilde

[TekBot]

Observe Medical ASA - Notice of Annual General Meeting

Oslo, May 3, 2024 - Observe Medical ASA (OBSRV): The annual general meeting of
Observe Medical ASA will be held on Friday, May 24, 2024, at 10:00 (CET).

…

Vis børsmeldingen

The annual general meeting will be held at Haakon VIIs gt. 1, 7th floor at
Reiten & CO, 0161 Oslo, Norway.

The Notice of the Annual General Meeting is attached, together with the
attendance, advance vote, and proxy forms.

The Notice is posted electronically or by mail to all shareholders and is
available on the company’s website www.observemedical.com.

For further information, please contact:

Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, Interim CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed
to improving patient welfare and patient outcomes, improving clinical data
accuracy and promoting positive health economics. The Company seeks to drive
growth by leveraging its expertise in sales and commercialization of its broad
portfolio of medical technology products, mainly in urine measurement,
ultrasound, anesthesiology/ICUs, surgery and wound care, in combination with
targeted M&A.

The Company is headquartered in Oslo, Norway, with additional offices in
Narvik, Norway and Gothenburg, Sweden, and subsidiaries in Finland and the US.
In addition, Observe Medical has a direct sale organization in the Nordics and
a distributor network internationally.

Further information is available at www.observemedical.com.

Kilde

[Hamara]

Hei! Noen som reagerer på styrehonorarene i selskapet? Tatt i betraktning selskapsstørrelse og selskapets økonomiske situasjon.

[Powertrade]

Tid for gode nyheter snart?

[TekBot]

Observe Medical ASA - Disclosure of voting rights at the Annual General meeting

Oslo, 23 May 2024: In connection with the annual general meeting of Observe
Medical ASA (the “Company”) to be held on 24 May 2024 (the “AGM”), Terje Bakken,
chairman of the board of directors of the Company, has received proxies without
…

Vis børsmeldingen

voting instructions for 24,286,193 shares or 12.24% of the total shares and
voting rights in the Company. The proxies are only valid at the AGM.

In addition, Terje Bakken represents Ingerø Reiten Investment Company AS at the
board of directors of the Company, who holds 37,384,437 shares or 19.61% of the
total shares and voting rights in the Company.

Hence, following the receipt of the proxy, Terje Bakken controls 31.85% of the
total shares and voting rights in the Company at the AGM.

This information is subject to the disclosure requirements pursuant to section 4
-2 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Observe Medical ASA - Update on disclosure of voting rights at the Annual General meeting

Oslo, 23 May 2024: In connection with the annual general meeting of Observe
Medical ASA (the “Company”) to be held on 24 May 2024 (the “AGM”), Terje Bakken,
chairman of the board of directors of the Company, has received proxies without
…

Vis børsmeldingen

voting instructions for 24,286,193 shares or 12.24% of the total shares and
voting rights in the Company. The proxies are only valid at the AGM.

This information is subject to the disclosure requirements pursuant to section 4
-2 of the Norwegian Securities Trading Act.

Please disregard previous announcement on this matter.

Kilde

[TekBot]

Observe Medical ASA - Minutes from Annual General Meeting

Observe Medical ASA has today, May 24, 2024, held the Annual General Meeting.
All resolutions were made in accordance with the board’s and the nomination
committee’s proposals. The minutes from the general meeting is attached hereto
…

Vis børsmeldingen

and will also be available at www.observemedical.com.

For further information, please contact:

Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com (rune.nystad@observemedical.com)

Johan M. Fagerli, Interim CFO of Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com (perarne.nygard@observemedical.com)

This information is subject of the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Observe Medical announces early launch of UnoMeter[TM] Safeti Plus

Oslo, 27 May 2024 - Observe Medical ASA (“the Company” or “Observe Medical”) is
pleased to announce the early launch of the UnoMeter[TM] Safeti Plus, a market
-leading Hourly Diuresis Monitoring System with a proven track record of safety
…

Vis børsmeldingen

and effectiveness.

This early launch is a direct result of the strong collaboration between Observe
Medical’s product development team and our external manufacturing partner. The
UnoMeterT Safeti Plus has enjoyed decades of success under Convatec, accounting
for the majority of the company’s historical sales in this segment.

The UnoMeterT Safeti Plus joins the existing UnoMeterT 500 and UnoMeterT Abdo
-PressureT products, creating a comprehensive UnoMeterT portfolio. This
portfolio positions Observe Medical for significant revenue growth and continued
geographical expansion.

The UnoMeterT Safeti Plus launch marks a major milestone in Observe Medical’s
strategic journey. It also lays the groundwork for the upcoming launch of
UnoMeterT Sippi, the next generation of hourly diuresis monitoring solutions.

For further information, please contact:

Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Rune Nystad, CDO Observe Medical
Mobile: +47 916 24 683
E-mail: rune.nystad@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

Kilde

[Powertrade]

Dette går rette veien. Sakte men sikkert bygges sten på sten. Bra portefølje av medisinsk utstyr. Samarbeidsavtaler. Salget tikker oppover. Og flere får øynene opp for at bunnen er passert. Gleder meg til fortsettelsen​:innocent:

[TekBot]

Observe Medical ASA - Biim Agreement with Fresenius Medical Care Extended for 2 Years

Oslo, 31 May 2024 - Observe Medical ASA (“the Company” or “Observe Medical”)
announces that its subsidiary, Biim AS (“Biim”), has extended its agreement with
Fresenius Medical Care (“Fresenius”) for the supply of wireless pocketable
…

Vis børsmeldingen

ultrasound devices.

The initial agreement with Fresenius was entered into in October 2021, with a
one-year extension exercised in October 2023. This renewal extends the
partnership for an additional two years, until April 1, 2026.

Under the agreement, Biim will continue to supply Fresenius with their wireless
pocketable ultrasound devices for use in their dialysis clinics across the
United States. As of today, Biim has successfully delivered 285 units in select
Fresenius test clinics, positioning the Company for potential expansion to all
approx. 3,000 US clinics.

This renewal strengthens Biim’s position within the dialysis market and
demonstrates continued confidence from a leading global healthcare provider like
Fresenius.

For further information, please contact:

Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, Interim CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

Kilde

[Powertrade]

Nydelig. Det fortsetter å tikke inn med gode meldinger

Unders over hvor få som har fått øynene opp her

[Powertrade]

Sjekk gapet i ordrebilde. Sier litt om potensialet her……

Vi skal langt opp

Snarlig

[Quadruple]

@Powertrade

Vi skal langt opp

Du “jobber” så godt du kan, ser jeg.
Jeg har sagt det før. La oss slippe “Hegnar online” tilstander her.
Meldingen igår var ikke oppsiktsvekkende.
Tiden går og det er nå ett par år siden Nystad hausset denne avtalen med Fresenius.
Fortell gjerne om de “gode meldinger” som “tikker inn” hos deg.
Jeg har ikke sett noen så langt i år.
Men om det skulle komme en god melding så fyker nok kursen opp.

[Aaleby]

I kategorien hjernedøde forsøk på hauss:

[Midlang86]

etter close?

[TekBot]

Observe Medical provides update on strong UnoMeter[TM] momentum in UK and Irish markets

Oslo, 3 June 2024 - Observe Medical ASA (“the Company” or “Observe Medical”)
continues to see positive momentum in the re-adoption of its UnoMeterT brand of
medical devices into NHS and across private hospitals in the United Kingdom and
…

Vis børsmeldingen

Ireland.

Building on previous announcements, Observe Medical confirms that since the
start of 2024, UnoMeterT products have been delivered to over 30 hospitals
within 11 NHS Trusts in England. UnoMeterT 500 (urinemeter) and UnoMeterT
AbdopressureT (IAP) are experiencing strong demand, further solidified by their
inclusion on both the English and Scottish Urology Frameworks.

Positive news continues in Ireland as well, with UnoMeterT products delivered to
the National Drugs Catalogue (NDC) and anticipated availability in hospitals
within days. This widespread reacceptance reflects the ongoing enthusiasm from
clinicians, nurses, and end-users who value the effectiveness of UnoMeterT
devices.

For further information, please contact:

Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

Kilde